The credibility of model-based economic evaluations of Alzheimer’s disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer’s Disease (IPECAD) Modeling Workshop Challenge.
Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop.
A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia).
The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.
The full study can be viewed at Alzheimer’s & Dementia.
Handels, R. L., Green, C., Gustavsson, A., Herring, W. L., Winblad, B., Wimo, A., … & IPECAD modeling workshop 2020 participants. (2022). Cost‐effectiveness models for Alzheimer’s disease and related dementias: IPECAD modeling workshop cross‐comparison challenge. Alzheimer’s & Dementia.